모구형질세포양 수지상세포종양(BPDCN) : 신규 요법, 미충족 수요 및 TPP 인사이트 리포트(2026년)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Emerging Therapy and TPP Insights

Thelansis's "Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Overview

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive haematological malignancy driven by precursor plasmacytoid dendritic cells, causing violaceous, bruise-like skin nodules alongside marrow and lymph node infiltration. Diagnosis relies on a characteristic CD4, CD56, CD123, and TCL1 immunophenotyping profile. Tagraxofusp, a CD123-directed cytotoxin, is the frontline targeted standard, though its use mandates strict monitoring for capillary leak syndrome. In 2026, venetoclax-based BCL-2 inhibition combinations provide an essential alternative for tagraxofusp-ineligible cohorts, while novel CD123-targeted bispecifics are expanding relapsed therapies. Intensive leukemia-type regimens retain high clinical relevance as structural bridges to allogeneic stem cell transplantation, which offers the only curative option for patients achieving remission. Prognosis remains poor due to high relapse rates without a transplant, requiring early multidisciplinary coordination.

Key Highlights

• BPDCN is a rare, aggressive hematologic malignancy with high unmet need
• US incidence expected to increase from ~1.8K to ~2.4K (~3% CAGR)

Market Overview

• France market projected to grow from ~$8.3M to ~$17.4M (~7-8% CAGR)
• Growth driven by targeted therapies and improved diagnosis, despite small patient population

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• AbbVie
• Stemline Therapeutics

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)